Neuroimaging of the serotonin transporter: Possibilities and pitfalls

Peter Brust, Swen Hesse, Ulrich Müller, Zsolt Szabo

Research output: Contribution to journalArticle

Abstract

Nuclear clear medicine imaging techniques like positron emission tomography (PET) and single-photon emission computed tomography (SPECT) apply radiolabeled drugs that bind selectively to specific neurotransmitter receptors and transporters such as the serotonin transporter (SERT) in the living human brain. They can help overcome certain limitations of postmortem, platelet and genetic studies of the SERT. This review compares the outcome of those studies with recent neuroimaging findings. The first part of this review deals with the choice of radioligands used to quantify SERT distribution in the human brain. The second part summarizes studies performed to understand the normal physiology of the serotonergic system. Selective serotonin reuptake inhibitors (SSRIs), used to treat a wide range of neuropsychiatric disorders with emotional instability and behavioral control deficits, compete with SERT radioligands and have been investigated in pharmacological PET and SPECT studies in healthy volunteers and patients. Part three reviews SERT imaging studies in patients, which have meanwhile been performed in most disorders that benefit from SSRI treatment. It is hypothesized that serotonin deficits and neuropsychiatric symptoms are linked by the inhibition of involuntary emotional reactions to external and internal stimuli. This could explain, why the consistency of many SERT neuroimaging findings is low, and may help develop individual treatment strategies in therapy-nonresponsive cases and to engineer new drugs for the therapy of neuropsychiatric disorders.

Original languageEnglish (US)
Pages (from-to)111-149
Number of pages39
JournalCurrent Psychiatry Reviews
Volume2
Issue number1
DOIs
StatePublished - Feb 2006

Fingerprint

Serotonin Plasma Membrane Transport Proteins
Neuroimaging
Serotonin Uptake Inhibitors
Single-Photon Emission-Computed Tomography
Positron-Emission Tomography
Neurotransmitter Transport Proteins
Neurotransmitter Receptor
Nuclear Medicine
Brain
Serotonin
Healthy Volunteers
Therapeutics
Blood Platelets
Outcome Assessment (Health Care)
Pharmacology
Drug Therapy
Pharmaceutical Preparations

Keywords

  • Imaging
  • Neuropsychiatric disorders
  • Positron emission tomography
  • Serotonin transporter
  • Single photon computed tomography

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Neuroimaging of the serotonin transporter : Possibilities and pitfalls. / Brust, Peter; Hesse, Swen; Müller, Ulrich; Szabo, Zsolt.

In: Current Psychiatry Reviews, Vol. 2, No. 1, 02.2006, p. 111-149.

Research output: Contribution to journalArticle

Brust, Peter ; Hesse, Swen ; Müller, Ulrich ; Szabo, Zsolt. / Neuroimaging of the serotonin transporter : Possibilities and pitfalls. In: Current Psychiatry Reviews. 2006 ; Vol. 2, No. 1. pp. 111-149.
@article{ad6fb709003e4511b06339ccb551d409,
title = "Neuroimaging of the serotonin transporter: Possibilities and pitfalls",
abstract = "Nuclear clear medicine imaging techniques like positron emission tomography (PET) and single-photon emission computed tomography (SPECT) apply radiolabeled drugs that bind selectively to specific neurotransmitter receptors and transporters such as the serotonin transporter (SERT) in the living human brain. They can help overcome certain limitations of postmortem, platelet and genetic studies of the SERT. This review compares the outcome of those studies with recent neuroimaging findings. The first part of this review deals with the choice of radioligands used to quantify SERT distribution in the human brain. The second part summarizes studies performed to understand the normal physiology of the serotonergic system. Selective serotonin reuptake inhibitors (SSRIs), used to treat a wide range of neuropsychiatric disorders with emotional instability and behavioral control deficits, compete with SERT radioligands and have been investigated in pharmacological PET and SPECT studies in healthy volunteers and patients. Part three reviews SERT imaging studies in patients, which have meanwhile been performed in most disorders that benefit from SSRI treatment. It is hypothesized that serotonin deficits and neuropsychiatric symptoms are linked by the inhibition of involuntary emotional reactions to external and internal stimuli. This could explain, why the consistency of many SERT neuroimaging findings is low, and may help develop individual treatment strategies in therapy-nonresponsive cases and to engineer new drugs for the therapy of neuropsychiatric disorders.",
keywords = "Imaging, Neuropsychiatric disorders, Positron emission tomography, Serotonin transporter, Single photon computed tomography",
author = "Peter Brust and Swen Hesse and Ulrich M{\"u}ller and Zsolt Szabo",
year = "2006",
month = "2",
doi = "10.2174/157340006775101508",
language = "English (US)",
volume = "2",
pages = "111--149",
journal = "Current Psychiatry Reviews",
issn = "1573-4005",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Neuroimaging of the serotonin transporter

T2 - Possibilities and pitfalls

AU - Brust, Peter

AU - Hesse, Swen

AU - Müller, Ulrich

AU - Szabo, Zsolt

PY - 2006/2

Y1 - 2006/2

N2 - Nuclear clear medicine imaging techniques like positron emission tomography (PET) and single-photon emission computed tomography (SPECT) apply radiolabeled drugs that bind selectively to specific neurotransmitter receptors and transporters such as the serotonin transporter (SERT) in the living human brain. They can help overcome certain limitations of postmortem, platelet and genetic studies of the SERT. This review compares the outcome of those studies with recent neuroimaging findings. The first part of this review deals with the choice of radioligands used to quantify SERT distribution in the human brain. The second part summarizes studies performed to understand the normal physiology of the serotonergic system. Selective serotonin reuptake inhibitors (SSRIs), used to treat a wide range of neuropsychiatric disorders with emotional instability and behavioral control deficits, compete with SERT radioligands and have been investigated in pharmacological PET and SPECT studies in healthy volunteers and patients. Part three reviews SERT imaging studies in patients, which have meanwhile been performed in most disorders that benefit from SSRI treatment. It is hypothesized that serotonin deficits and neuropsychiatric symptoms are linked by the inhibition of involuntary emotional reactions to external and internal stimuli. This could explain, why the consistency of many SERT neuroimaging findings is low, and may help develop individual treatment strategies in therapy-nonresponsive cases and to engineer new drugs for the therapy of neuropsychiatric disorders.

AB - Nuclear clear medicine imaging techniques like positron emission tomography (PET) and single-photon emission computed tomography (SPECT) apply radiolabeled drugs that bind selectively to specific neurotransmitter receptors and transporters such as the serotonin transporter (SERT) in the living human brain. They can help overcome certain limitations of postmortem, platelet and genetic studies of the SERT. This review compares the outcome of those studies with recent neuroimaging findings. The first part of this review deals with the choice of radioligands used to quantify SERT distribution in the human brain. The second part summarizes studies performed to understand the normal physiology of the serotonergic system. Selective serotonin reuptake inhibitors (SSRIs), used to treat a wide range of neuropsychiatric disorders with emotional instability and behavioral control deficits, compete with SERT radioligands and have been investigated in pharmacological PET and SPECT studies in healthy volunteers and patients. Part three reviews SERT imaging studies in patients, which have meanwhile been performed in most disorders that benefit from SSRI treatment. It is hypothesized that serotonin deficits and neuropsychiatric symptoms are linked by the inhibition of involuntary emotional reactions to external and internal stimuli. This could explain, why the consistency of many SERT neuroimaging findings is low, and may help develop individual treatment strategies in therapy-nonresponsive cases and to engineer new drugs for the therapy of neuropsychiatric disorders.

KW - Imaging

KW - Neuropsychiatric disorders

KW - Positron emission tomography

KW - Serotonin transporter

KW - Single photon computed tomography

UR - http://www.scopus.com/inward/record.url?scp=31844433949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31844433949&partnerID=8YFLogxK

U2 - 10.2174/157340006775101508

DO - 10.2174/157340006775101508

M3 - Article

AN - SCOPUS:31844433949

VL - 2

SP - 111

EP - 149

JO - Current Psychiatry Reviews

JF - Current Psychiatry Reviews

SN - 1573-4005

IS - 1

ER -